Celaid Therapeutics
PrivateLast Round
Series B
Oct 5, 2026
Total Funding Raised
$34.14M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Celaid Therapeutics is a biotechnology company that develops a proprietary platform for the large-scale, ex vivo expansion of human hematopoietic stem cells for use in cell and gene therapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Celaid Therapeutics Comparables
Compare Celaid Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ExCellThera | 81% | |
| Fujifilm Holdings Corporation | 75% | |
| Nipro Corp | 73% |
Celaid Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 5, 2026 | ||||
| Series A Extension | Oct 31, 2024 | ||||
| Grant | Sep 30, 2024 | ||||
| Series A Extension | May 8, 2024 | ||||
| Grant | Mar 22, 2024 | ||||
Series A | Oct 25, 2022 |
Celaid Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Japan Agency for Medical Research and Development | Series B |
| Kobe University Capital | Series A Extension |
| Shionogi & Co. | Series B |
| UTEC (The University of Tokyo Edge Capital Partners) | Series B, Series A, Pre Seed, Series A Extension |
| Joyo Capital Partners | Series A Extension, Series B |
| Teikoku Ventures | Series B |
| SBI Regional Revitalization Support Corporation | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 5, 2026
$7.2M round completed.
- Nov 20, 2025
Selected for the Shonan Health Innovation Conference in Boston.
Celaid Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Celaid Therapeutics's valuation, stock price, and market status.
Is Celaid Therapeutics a public or private company?
Celaid Therapeutics is a private company.
What is the current stock price of Celaid Therapeutics?
Celaid Therapeutics is a private company, so its shares have no public market price. Caplight tracks Celaid Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Celaid Therapeutics worth (valuation)?
Valuation information for Celaid Therapeutics is not publicly available.
Can I buy Celaid Therapeutics stock?
Celaid Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Celaid Therapeutics's last funding round?
Celaid Therapeutics's most recent funding round was Series B on October 5, 2026.
Who are the main investors in Celaid Therapeutics?
Key investors in Celaid Therapeutics include UTEC (The University of Tokyo Edge Capital Partners), Osaka University Venture Capital Co., Ltd..
Will Celaid Therapeutics IPO soon?
No public IPO plans have been announced for Celaid Therapeutics.
How can I track Celaid Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Celaid Therapeutics's shares on secondary markets.